Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations

Anderson S(2012)Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed paraffin-embedded tissue specimens of malignant melanoma Arch Pathol Lab Med 136 1385-1391

Bloom KJ(2011)Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry J Mol Diagn 13 504-513

Vallera DU(2011)Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2507-2516

Rueschoff J(2012)BRAF/NRAS mutation frequencies among primary tumours and metastases in patients with melanoma J Clin Oncol 30 2522-2529

Meldrum C(2005)Distinct sets of genetic alterations in melanoma N Engl J Med 353 2135-2147

Schilling R(2011)Spectrum of KIT/PDGFRA/BRAF mutations and phosphatidylinositol-3-kinase pathway gene alterations in gastrointestinal stromal tumors (GIST) Cancer Lett 312 43-54

Kovach B(2010)Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 809-819

Lee JR(2012)Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 883-892

Ochoa P(2012)Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 358-365

Langland R(2013)Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice Br J Cancer 108 2164-2171

Anderson S(2012)Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed paraffin-embedded tissue specimens of malignant melanoma Arch Pathol Lab Med 136 1385-1391

Bloom KJ(2011)Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry J Mol Diagn 13 504-513

Vallera DU(2011)Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2507-2516

Rueschoff J(2012)BRAF/NRAS mutation frequencies among primary tumours and metastases in patients with melanoma J Clin Oncol 30 2522-2529

Meldrum C(2005)Distinct sets of genetic alterations in melanoma N Engl J Med 353 2135-2147

Schilling R(2011)Spectrum of KIT/PDGFRA/BRAF mutations and phosphatidylinositol-3-kinase pathway gene alterations in gastrointestinal stromal tumors (GIST) Cancer Lett 312 43-54

Kovach B(2010)Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 809-819

Lee JR(2012)Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 883-892

Ochoa P(2012)Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 358-365

Langland R(2013)Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice Br J Cancer 108 2164-2171